SEVENFACT® to reduce bleeding in hemophilia with inhibitors
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial studies whether SEVENFACT® can reduce bleeding episodes in people with hemophilia A or B who have inhibitors (proteins that make standard treatments less effective). It also tests how well people can track bleeding and medicine use during the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hemophilia A or hemophilia B and you have inhibitors
- You are at least 12 years old
- You (or your legal guardian) can understand the study and follow its rules
- You can provide records showing your past inhibitor levels
- You agree to record bleeding events and medicines using the study app or a paper diary
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
This trial tests a new drug called KN057 for people with severe hemophilia A or moderate-to-severe hemophilia B, whether or not they have developed inhibitors (antibodies that block standard treatments). The goal is to see if it can help prevent or treat bleeding episodes.
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
This trial tests a new medicine called NXT007 to see if it is safe and effective for people with severe or moderate hemophilia A, including those with inhibitors. It may help reduce bleeding episodes.
This trial tests a new long-acting factor VIII treatment (FRSW107) for people with severe hemophilia A. It aims to prevent bleeding episodes with fewer injections, and you must have already used factor VIII treatments many times before.
This early-stage trial tests a new injectable medicine called SR604 designed to help people with hemophilia A, hemophilia B, or congenital Factor VII deficiency—conditions where the blood doesn't clot properly. The study will look at how safe the medicine is and whether it reduces bleeding episodes.
Hear when a new Hemophilia A With Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.